59 related articles for article (PubMed ID: 11507072)
1. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.
Kawakami M; Kawakami K; Puri RK
Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421
[TBL] [Abstract][Full Text] [Related]
3. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.
Mintz A; Gibo DM; Slagle-Webb B; Christensen ND; Debinski W
Neoplasia; 2002; 4(5):388-99. PubMed ID: 12192597
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma.
Liu H; Jacobs BS; Liu J; Prayson RA; Estes ML; Barnett GH; Barna BP
Cancer Immunol Immunother; 2000 Aug; 49(6):319-24. PubMed ID: 10946814
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.
Ou W; Marino MP; Suzuki A; Joshi B; Husain SR; Maisner A; Galanis E; Puri RK; Reiser J
Hum Gene Ther Methods; 2012 Apr; 23(2):137-47. PubMed ID: 22612657
[TBL] [Abstract][Full Text] [Related]
6. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide.
Jannoo R; Walker W; Kanamarlapudi V
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345109
[TBL] [Abstract][Full Text] [Related]
7. Targeting IL-13Rα2 for effective treatment of malignant peripheral nerve sheath tumors in mouse models.
Mrowczynski OD; Payne RA; Bourcier AJ; Mau CY; Slagle-Webb B; Shenoy G; Madhankumar AB; Abramson SB; Wolfe D; Harbaugh KS; Rizk EB; Connor JR
J Neurosurg; 2018 Nov; 131(5):1369-1379. PubMed ID: 30544352
[TBL] [Abstract][Full Text] [Related]
8. Distinct nitrogen isotopic compositions of healthy and cancerous tissue in mice brain and head&neck micro-biopsies.
Straub M; Sigman DM; Auderset A; Ollivier J; Petit B; Hinnenberg B; Rubach F; Oleynik S; Vozenin MC; Martínez-García A
BMC Cancer; 2021 Jul; 21(1):805. PubMed ID: 34256713
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 May; 30(5):1501. PubMed ID: 38514871
[No Abstract] [Full Text] [Related]
10. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
11. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer.
Shi J; Song X; Traub B; Luxenhofer M; Kornmann M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804263
[TBL] [Abstract][Full Text] [Related]
12. Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Kang MA; Lee J; Ha SH; Lee CM; Kim KM; Jang KY; Park SH
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540495
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors.
Madhankumar AB; Mrowczynski OD; Slagle-Webb B; Ravi V; Bourcier AJ; Payne R; Harbaugh KS; Rizk E; Connor JR
PLoS One; 2018; 13(1):e0181529. PubMed ID: 29304038
[TBL] [Abstract][Full Text] [Related]
14. Prioritization schema for immunotherapy clinical trials in glioblastoma.
Hodges TR; Ferguson SD; Caruso HG; Kohanbash G; Zhou S; Cloughesy TF; Berger MS; Poste GH; Khasraw M; Ba S; Jiang T; Mikkelson T; Yung WK; de Groot JF; Fine H; Cantley LC; Mellinghoff IK; Mitchell DA; Okada H; Heimberger AB
Oncoimmunology; 2016 Jun; 5(6):e1145332. PubMed ID: 27471611
[TBL] [Abstract][Full Text] [Related]
15. Nucleic acid targeting: towards personalized therapy for head and neck cancer.
Parsel SM; Grandis JR; Thomas SM
Oncogene; 2016 Jun; 35(25):3217-26. PubMed ID: 26592450
[TBL] [Abstract][Full Text] [Related]
16. IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.
Xie M; Wu XJ; Zhang JJ; He CS
Oncotarget; 2015 Oct; 6(32):32902-13. PubMed ID: 26418721
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients.
Green VL; Michno A; Greenman J; Stafford ND
Results Immunol; 2011; 2():1-6. PubMed ID: 24371560
[TBL] [Abstract][Full Text] [Related]
18. Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.
Hall B; Nakashima H; Sun ZJ; Sato Y; Bian Y; Husain SR; Puri RK; Kulkarni AB
J Transl Med; 2013 Feb; 11():45. PubMed ID: 23421960
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma.
Zhang L; Sun ZJ; Bian Y; Kulkarni AB
Cancer Lett; 2013 May; 331(2):230-8. PubMed ID: 23340180
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
